# EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer

> **NCT00049231** · NA · COMPLETED · sponsor: **Gynecologic Oncology Group**

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** EF5
- **OTHER:** immunohistochemistry staining method
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00049231
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049231, "EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00049231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*